debate 2: braf mutant mcrc patients - folfirinox/bev
Published 9 years ago • 369 plays • Length 8:27Download video MP4
Download video MP3
Similar videos
-
13:59
debate 2: braf mutant mcrc patients - clinical trial
-
4:51
colorectal cancer debate: first line braf v600e - folfoxiri/bev
-
11:54
debate: targeted therapy for ras/braf wt left sided colon cancers - bevacizumab or egfr antibodies
-
6:06
colorectal cancer debate: first line braf v600e - targeted triplet
-
1:24
fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
-
12:31
folfiri side effects
-
22:50
update: left versus right sided colon cancers: biomarkers versus biology
-
12:54
my experience in the beginning with folfox and folfiri chemo
-
15:52
debate: are novel targets such as her2 ready for prime time in colorectal cancer? - no
-
10:42
brca pancreatic cancer maintenance debate: parp inhibitor or continued chemo? - parp inhibitor
-
11:15
debate: borderline resectable liver metastasis in ras wt crc? - folfox (or folfoxiri)/bev
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
1:55
dr. lieu on the predictive value of braf v600e mutations in crc
-
1:35:47
braf-mutated mcrc: from diagnosis to treatment
-
2:18
prognosticating braf-mutant mcrc
-
18:33
gemcitabine monotherapy vs. doublet therapy vs. folfirinox for metastatic pancreatic adenocarcinoma
-
8:46
debate: optimal chemotherapy backbone for targeted agents in pancreatic cancer? - folfirinox
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
10:30
debate 1: first-line treatment of metastatic colorectal cancer - fire-3
-
1:26
novel treatment strategies for braf v600e-mutant nsclc